Repositorio Dspace

Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma

Mostrar el registro sencillo del ítem

dc.contributor.author Martin-Moro, Fernando
dc.contributor.author Muntanola, Ana
dc.contributor.author Gutiérrez, Xabier
dc.contributor.author Vázquez, María-Sofia
dc.contributor.author Morais, Lucía
dc.contributor.author Amarika, Itxaso
dc.contributor.author Diez-Feijoo, Ramon
dc.contributor.author Bastos-Oreiro, Mariana
dc.contributor.author de-la-Cruz, Beatriz
dc.contributor.author Marco-Ayala, Javier
dc.contributor.author Ramos, Sergio
dc.contributor.author Jiménez-Ubieto, Ana
dc.contributor.author Galindo-Navarro, Pablo
dc.contributor.author Correa, Juan-Gonzalo
dc.contributor.author Lavilla, Esperanza
dc.contributor.author García-Herce, Cristina
dc.contributor.author Moreno, Miriam
dc.contributor.author Domingo-Domenech, Eva
dc.contributor.author Domínguez, Nazaret
dc.contributor.author Alonso, Aranzazu
dc.contributor.author Otero, María-José
dc.contributor.author Comai, Alessandra
dc.contributor.author Bengochea, María-Luisa
dc.contributor.author Da-Ros, Carolina-Villegas
dc.contributor.author Gutiérrez, Norma-C
dc.contributor.author Lluch, Rafael
dc.contributor.author Fernández-Luis, Sara
dc.contributor.author Soler, Joan-Alfons
dc.contributor.author Cannata-Ortiz, M-Jimena
dc.contributor.author Medina, Ángeles
dc.contributor.author Martin-Consuegra, Sofia
dc.contributor.author Aceituno, Marta
dc.contributor.author Villafuerte, Paola
dc.contributor.author de-Miguel, Dunia
dc.contributor.author Arguinano, José-María
dc.contributor.author López, Javier
dc.contributor.author Villalon, Lucía
dc.contributor.author Gulino, Horacio
dc.contributor.author López-Guillermo, Armando
dc.contributor.author Salar, Antonio
dc.date.accessioned 2026-11-11T09:07:21Z
dc.date.available 2026-11-11T09:07:21Z
dc.date.issued 2026-10-27
dc.identifier.citation Martin-Moro F, Muntañola A, Gutiérrez X, Vázquez MS, Morais L, Amarika I, et al. Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. Blood Advances. 27 de octubre de 2026;10(20):7036-47. doi:10.1182/bloodadvances.2026020480
dc.identifier.issn 2473-9529
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29207
dc.description.abstract There is no established standard treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL). Zanubrutinib was approved in this setting based on the phase 2 MAGNOLIA trial. We retrospectively evaluated the characteristics and outcomes of 118 real-world patients in Spain with R/R MZL treated with zanubrutinib after at least 1 previous anti-CD20-based regimen. The median age at zanubrutinib initiation was 75 years, and 56% were female. MZL subtypes included splenic (55.3%), mucosa-associated lymphoid tissue (18.9%), nodal (19.8%), and nonclassifiable (6%). The median number of previous lines of therapy (LoT) was 1.5 (range, 1-7); 26% of patients had MZL refractory to the immediately preceding line, and 59% experienced progression of disease within 24 months (POD24) to frontline therapy. In total, 31 patients (26.3%) would not have met MAGNOLIA trial eligibility criteria, 68% had cardiovascular comorbidities, and 28% were receiving antithrombotic therapy. The overall and complete response rates were 76% and 22.2%, respectively, with no differences according to MZL subtype, age, POD24, or MAGNOLIA trial eligibility. Fewer previous LoT were associated with higher and deeper responses. With a median follow-up of 14 months, 1-year progression-free and overall survival were 79.4% and 86.8%, respectively. Zanubrutinib responders and patients with stable disease presented better outcomes than those with progressing disease (P< .01). Adverse events (AEs) were reported in 34.1% of patients (grade ?3 in 14.4%). MAGNOLIA trial-ineligible patients experienced a higher incidence of AEs, and bleeding events were more frequent among patients receiving anticoagulant therapy (P = .04). Overall, zanubrutinib demonstrated favorable effectiveness and safety in real-world R/R MZL, with improved outcomes when administered earlier in the disease.
dc.language.iso eng
dc.publisher ELSEVIER
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Female
dc.subject.mesh Lymphoma, B-Cell, Marginal Zone/drug therapy/mortality/pathology
dc.subject.mesh Spain
dc.subject.mesh Aged
dc.subject.mesh Male
dc.subject.mesh Aged, 80 and over
dc.subject.mesh Treatment Outcome
dc.subject.mesh Middle Aged
dc.subject.mesh Retrospective Studies
dc.subject.mesh Recurrence
dc.subject.mesh Neoplasm Recurrence, Local/drug therapy
dc.title Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42641154
dc.relation.publisherversion https://ashpublications.org/bloodadvances/article/10/20/7036/570523/Real-world-effectiveness-and-safety-of
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1182/bloodadvances.2026020480
dc.journal.title Blood Advances
dc.identifier.essn 2473-9537


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta